US20010008636A1 - Microparticulate surgical adhesive - Google Patents
Microparticulate surgical adhesive Download PDFInfo
- Publication number
- US20010008636A1 US20010008636A1 US09/352,615 US35261599A US2001008636A1 US 20010008636 A1 US20010008636 A1 US 20010008636A1 US 35261599 A US35261599 A US 35261599A US 2001008636 A1 US2001008636 A1 US 2001008636A1
- Authority
- US
- United States
- Prior art keywords
- adhesive composition
- composition according
- activatable
- adhesive
- microparticles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003106 tissue adhesive Substances 0.000 title claims abstract description 10
- 239000000463 material Substances 0.000 claims abstract description 52
- 239000000203 mixture Substances 0.000 claims abstract description 52
- 230000009969 flowable effect Effects 0.000 claims abstract description 16
- 238000002604 ultrasonography Methods 0.000 claims abstract description 4
- 239000000853 adhesive Substances 0.000 claims description 80
- 230000001070 adhesive effect Effects 0.000 claims description 80
- 108010010803 Gelatin Proteins 0.000 claims description 42
- 229920000159 gelatin Polymers 0.000 claims description 42
- 239000008273 gelatin Substances 0.000 claims description 42
- 235000019322 gelatine Nutrition 0.000 claims description 42
- 235000011852 gelatine desserts Nutrition 0.000 claims description 42
- 239000011859 microparticle Substances 0.000 claims description 40
- 239000004005 microsphere Substances 0.000 claims description 38
- 239000003094 microcapsule Substances 0.000 claims description 24
- 230000004913 activation Effects 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 20
- 239000002245 particle Substances 0.000 claims description 20
- 239000007787 solid Substances 0.000 claims description 18
- 239000002002 slurry Substances 0.000 claims description 14
- 102000008186 Collagen Human genes 0.000 claims description 12
- 108010035532 Collagen Proteins 0.000 claims description 12
- 108010049003 Fibrinogen Proteins 0.000 claims description 12
- 102000008946 Fibrinogen Human genes 0.000 claims description 12
- 229920001436 collagen Polymers 0.000 claims description 12
- 229940012952 fibrinogen Drugs 0.000 claims description 12
- 238000011065 in-situ storage Methods 0.000 claims description 11
- 229920001169 thermoplastic Polymers 0.000 claims description 10
- 238000004132 cross linking Methods 0.000 claims description 9
- 108010071289 Factor XIII Proteins 0.000 claims description 8
- 239000011248 coating agent Substances 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 229940012444 factor xiii Drugs 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 239000003431 cross linking reagent Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 230000010354 integration Effects 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 238000007789 sealing Methods 0.000 claims description 3
- 230000010102 embolization Effects 0.000 claims description 2
- 230000004927 fusion Effects 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000005482 chemotactic factor Substances 0.000 claims 1
- 238000010791 quenching Methods 0.000 claims 1
- 230000000171 quenching effect Effects 0.000 claims 1
- 239000003357 wound healing promoting agent Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 abstract description 18
- 230000008439 repair process Effects 0.000 abstract description 4
- 229920000642 polymer Polymers 0.000 description 23
- 238000001994 activation Methods 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 11
- 238000002156 mixing Methods 0.000 description 9
- 238000010438 heat treatment Methods 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000002480 mineral oil Substances 0.000 description 7
- 235000010446 mineral oil Nutrition 0.000 description 7
- 229920001223 polyethylene glycol Polymers 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 108010073385 Fibrin Proteins 0.000 description 6
- 102000009123 Fibrin Human genes 0.000 description 6
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000006185 dispersion Substances 0.000 description 6
- 229950003499 fibrin Drugs 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 238000006116 polymerization reaction Methods 0.000 description 6
- 239000004416 thermosoftening plastic Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 5
- 238000006065 biodegradation reaction Methods 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 239000004823 Reactive adhesive Substances 0.000 description 4
- 108090000190 Thrombin Proteins 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 229920002988 biodegradable polymer Polymers 0.000 description 4
- 239000004621 biodegradable polymer Substances 0.000 description 4
- 229920001222 biopolymer Polymers 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000008367 deionised water Substances 0.000 description 4
- 229910021641 deionized water Inorganic materials 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229920002674 hyaluronan Polymers 0.000 description 4
- 229960003160 hyaluronic acid Drugs 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000747 poly(lactic acid) Polymers 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000010512 thermal transition Effects 0.000 description 4
- 229960004072 thrombin Drugs 0.000 description 4
- 229920001651 Cyanoacrylate Polymers 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-M acrylate group Chemical group C(C=C)(=O)[O-] NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000005354 coacervation Methods 0.000 description 3
- 229920006237 degradable polymer Polymers 0.000 description 3
- 238000005538 encapsulation Methods 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 238000001694 spray drying Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 238000003466 welding Methods 0.000 description 3
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 2
- 108010080379 Fibrin Tissue Adhesive Proteins 0.000 description 2
- MWCLLHOVUTZFKS-UHFFFAOYSA-N Methyl cyanoacrylate Chemical compound COC(=O)C(=C)C#N MWCLLHOVUTZFKS-UHFFFAOYSA-N 0.000 description 2
- 239000004825 One-part adhesive Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000003364 biologic glue Substances 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 238000010382 chemical cross-linking Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000005442 diisocyanate group Chemical group 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 230000009477 glass transition Effects 0.000 description 2
- 230000036571 hydration Effects 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000002787 reinforcement Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000003894 surgical glue Substances 0.000 description 2
- 229920001059 synthetic polymer Polymers 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- OLBMELGQHWGHTL-UHFFFAOYSA-N 1-(ethyliminomethylideneamino)-n,n'-dimethylpropane-1,3-diamine;hydrochloride Chemical compound Cl.CCN=C=NC(NC)CCNC OLBMELGQHWGHTL-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229910001369 Brass Inorganic materials 0.000 description 1
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000010752 Plasminogen Inactivators Human genes 0.000 description 1
- 108010077971 Plasminogen Inactivators Proteins 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000004826 Synthetic adhesive Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010951 brass Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 230000009920 chelation Effects 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000012936 correction and preventive action Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000011243 crosslinked material Substances 0.000 description 1
- NLCKLZIHJQEMCU-UHFFFAOYSA-N cyano prop-2-enoate Chemical class C=CC(=O)OC#N NLCKLZIHJQEMCU-UHFFFAOYSA-N 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000004815 dispersion polymer Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000011213 glass-filled polymer Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010952 in-situ formation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008204 material by function Substances 0.000 description 1
- 238000004137 mechanical activation Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000011236 particulate material Substances 0.000 description 1
- 230000016446 peptide cross-linking Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000002797 plasminogen activator inhibitor Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- -1 polyhydroxybuterate Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000565 sealant Substances 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000007725 thermal activation Methods 0.000 description 1
- 229940075469 tissue adhesives Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- VOITXYVAKOUIBA-UHFFFAOYSA-N triethylaluminium Chemical compound CC[Al](CC)CC VOITXYVAKOUIBA-UHFFFAOYSA-N 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/106—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/043—Mixtures of macromolecular materials
Definitions
- the invention relates to surgical adhesives, and in particular to adhesives which are formed by combination or reaction of their components (hereinafter, “activated”) at the wound site.
- Surgical adhesives have long been of interest for reconstructing tissues due to the ease of applicability and combined mechanical securement and sealing function.
- Modern forms of fibrin adhesives incorporate enzyme inhibitors not only for practical workability, but to retard in-vivo degradation and loss of strength as described in U.S. Pat. No. 4,298,598. Still, these fibrin adhesives require the mixing of two components with long reconstitution times and demonstrate limited and variable working time before setting.
- the use of human pooled blood in these products has raised concern regarding potential viral contamination and transmission.
- Synthetic adhesive systems such as the cyanoacrylates and cyanobutylates have high adhesive strength, but have poor degradation properties, with toxic byproducts such as formaldehyde being formed. Further, these materials are mechanically stiff and have poor integration properties with healing tissues.
- the cyanoacrylate type adhesive systems incorporate almost pure monomer which is initiated by water to form a high strength polymer. The rapidly setting adhesive is difficult to apply in some cases, especially in endoscopic use where the adhesive can set within the catheter lumen.
- Synthetic prepolymer approaches such as described in U.S. Pat. No. 4,804,691 may utilize biodegradable polymer components, but often rely on toxic components such as isocyanates and metal catalysts. Small amounts of toxicity may have adverse effect on the critical tissue to adhesive interface of a surgical adhesive.
- a method described in U.S. Pat. No. 5,156,613 describes the use of a solid collagen filler material which is applied to tissues while an energy source heats both the tissues and the filler material as a tissue welding aid.
- the denaturation of the tissues and filler, upon cooling provides a mechanical bond.
- the approach utilizes high solids content adhesive, essentially a solid, the resultant adhesive material is held together by chain entanglement of the collagen/gelatin chains, limiting mechanical strength and biodegradation resistance.
- the inherent damage to underlying tissues of tissue welding approaches in general may prevent use on or near sensitive tissues such as fragile vasculature, nervous tissue, ocular tissue, and areas of cosmetic concern such as the face and neck.
- a similar approach is described in U.S. Pat.
- the present invention describes novel tissue adhesives comprising a flowable polymeric microparticulate formulation which can be site activated to produce a cohesive material with tissue bonding properties to adjacent tissues.
- the material can be used to join tissues, seal tissue junctions, act as an injectable embolization agent, augment tissues and reinforce organ walls.
- microparticulates allows facile applicability as a powder or paste to tissues, with the microparticles able to flow into the tissue crevices and set into the appropriate conformation.
- Further objects are to provide a formulation for flowable systems, to prevent damage to contacting tissues during application of the adhesive and biodegradation, to control the degradation rate of the adhesive, and to provide tissue ingrowth features in an adhesive to provide a gradual load transfer to the healing tissues.
- FIG. 1 shows the activation of the surface of microparticles to form a solid material by polymer bridging.
- FIG. 2 shows the activation of a polymerization mechanism by the mixing of encapsulated reagents A and B to form a product C.
- FIG. 3 shows the formation of a material with channels formed by activation of a particulate polymer composition.
- FIG. 4 shows activation of a flowable microparticulate formulation at the tip of a catheter with heat generating elements, D, to deliver a molten polymer adhesive.
- FIG. 5 shows activation of a flowable microcapsule formulation at the tip of a catheter with a rotating outer shaft, E, to spin a rotor, F, in the flow path to mechanically disrupt the microcapsules and deliver an initiated adhesive.
- the microparticulate adhesive comprises biodegradable components to allow for natural degradation and progressive incorporation with newly formed tissue. This is particularly important for the clinical success of a surgical adhesive as rapid mechanical failure of the adhesive may lead to clinical problems.
- Preferred components are biodegradable polymers including biopolymers such as collagen, gelatin, elastin, hyaluronic acid, and fibrin; synthetic degradable polymers such as poly lactic/glycolic acid polymers and copolymers, polyhydroxybuterate, and polycaprolactone; and biological polymerization components such as fibrinogen and factor XIII.
- Biopolymers such as collagen and gelatin in particular provide a progressive degradation and load transfer to the healing tissues which would be preferred for clinical efficacy.
- the tissue integration of the surgical adhesive with the healing tissues may be further promoted by the formation of a porous structure by the microspheres in-situ, thereby allowing tissue ingrowth and mechanical interlocking.
- Other components such as growth factors and chemotactic agents, may also be incorporated into the adhesive to further increase tissue incorporation and the performance of the tissue repair.
- insoluble microparticles in a solvent mixture greatly reduces viscosity and allows the use of a very high solids content formulation that is flowable.
- a typical collagen or gelatin composition can achieve solids contents up to approximately 10 to 20 weight % before the viscosity of the polymer increases to form a non-flowable solid.
- flowable solids contents of approximately 50 weight % can be achieved.
- the solvent vehicle in a polymeric adhesive such as water, does not participate in forming a structural adhesive, it is important to maximize the amount of structural polymer that is delivered as an adhesive. Small amounts of reactive adhesive components or flow enhancers, may be incorporated into the solvent vehicle for the microparticles, especially if they are of lower molecular weight to prevent viscosity limitations.
- microparticles or microspheres not only allows high solids content, flowable formulations, but also allows activatable components to be packaged within hollow or surface coated constructs similar to industrial one part adhesives. While the typical encapsulation of a catalyst in an industrial one-part adhesive utilizes rigid, fracturable materials such as glass, silica, and rigid thermoplastics to enhance rupture efficiency, these types of materials are not toxicologically acceptable for implantation in tissues.
- the present invention utilizes microcapsules fabricated entirely from biodegradable polymers that can are rupturable by careful control of capsule thickness, and, optionally, by use of chemical surface stabilization.
- hollow microspheres or microcapsules are fabricated from biodegradable materials and packed with reactive components such as synthetic or biological polymerization systems.
- the reactive components may be isolated in discreet capsules, which polymerize to form an adhesive when the capsules are broken by mechanical shear and mixed, such as at the end of a delivery catheter.
- An illustration of this method is shown in FIG. 5.
- An example is the packaging of fibrinogen in microcapsules with separate microcapsules of thrombin. Upon mechanical rupture, the components react to form a fibrin adhesive.
- reactive adhesive components may be packaged within water insoluble capsules and delivered in an non-aqueous solvent to be activated in situ by hydration.
- Activation methods other than mechanical shear can be utilized with the microcapsules or microparticles. Heat can be used to flow and/or rupture the particles by tailoring the thermal transition properties of the particulate materials. An illustration of that method is shown in FIG. 4. Both biopolymers and biodegradable synthetic polymers have thermal transitions such as the glass transition temperature, which can be tailored for use as adhesive microparticles. Physical methods such as ultrasound can be used in a combined mechanical/thermal activation method. Radio frequency and microwave excitation, while having some patient shielding concerns, may also be utilized to thermally activate or rupture the microparticles to initiate the adhesive.
- Typical linkages used include covalent crosslinks either formed chemically or enzymatically, strong ionic interactions such as chelation, strong hydrophobic interactions, or inter-chain entanglement of polymers.
- covalent crosslinking and/or chain entanglement are preferred.
- chain entanglement alone such as the application of a heat activatable thermoplastic polymer component, it is important that the glass transition of the polymer be above physiological temperature to form a stable material. Otherwise, the resultant material would lack material integrity within the body, as occurs with non-crosslinked gelatin, for example, with a transition temperature of about 37° centigrade.
- microparticles or microcapsules are fabricated from high strength degradable polymers with affinity for the adhesive components.
- the wall components will be incorporated into the final adhesive material, acting as particulate reinforcements, similar to glass filled polymers.
- the same structural properties which allow the microcapsule to resist premature rupture during use can be further tailored to provide structural reinforcement of the adhesive material, especially controllable by crosslinking the capsule material for the proper biodegradation rate.
- microparticles may not be necessary or desired to rupture the microparticles.
- a flowable component which can be set into a solid, or by activating the surface of the microparticles, polymer bridges between particles may be formed to provide structural material from the joined particles, similar to a sintered polymer. Suitable activation methods may be used, such as heat to activate a thermoplastic polymer component or coating of the microparticles.
- Other particle bridging components include collagen and gelatin, which will flow upon controlled heating and can be further enhanced by a thermoplastic coating or chemical surface graft such as polylactic/glycolic acid polymers.
- non-encapsulated polymer or reactive components such as difunctional epoxides reagents may be used to facilitate adhesive setting.
- Other particle bridging methods include optically activatable groups such as acrylate functional materials which may be incorporated onto the microparticles or formulated as a non-encapsulated component.
- Degradable microparticles may be used which to rapidly degrade and form a porous network during biodegradation allowing tissue ingrowth and progressive load transfer to the healing tissues, which is ideal for preventing failure of the surgical adhesive repair.
- the degradable microparticles may be fabricated by many available methods. Dry materials can be pulverized and sieved to produce irregular solid particles of selected size range. Irregular particles, while simple to fabricate, tend to pack and clog during flow at high solids contents. Microspheres, with a smooth outer surface have less tendency to interlock with other particles, allowing for increased solids content of a flowable formulation. Microspheres can be fabricated by a variety of method including spray drying, coacervation/emulsion methods, and droplet coagulation. In a preferred method for making hollow microspheres, a limited amount of cross-linking agent can be applied to solid microspheres, then the cross-linking reaction is quenched. The uncrosslinked centers may be extracted with a suitable solvent which swells the cross-linked shell and dissolves the uncrosslinked centers.
- Polymeric microspheres may be further tailored after fabrication by chemical crosslinking to control solubility and biodegradation properties, and also chemically grafted or coated for chemical activation.
- Microspheres with hollow cavities may be used to isolate reactive adhesive components.
- Such microcapsules may be formed with single or multiple cavities by methods such as interfacial deposition, spray drying over a removable core, and the like.
- To package the reactive components they may be formed into particles and coated during fabrication into microspheres.
- some reactive components of low molecular weight may be incorporated by swelling the prefabricated microcapsules with a solution of the component and allowing for diffusion into the microcapsule interior.
- the biodegradable microparticles have an activatable mechanism to allow in-situ formation of a cohesive material.
- Heat can be used to fuse the microparticulate surfaces together with the degree controlled by the microparticle surface composition and thermal transition properties.
- gelatin particles are fused together to form a cohesive mass upon heating at the end of a catheter tip.
- the gelatin thermal transition may be altered by the selection of the gelatin molecular weight, degree of deamidation, the type and extent of side chain modifications, and the degree of chemical crosslinking with difunctional chemical agents such as dialdehydes and diisocyanates or peptide crosslinking agents such as carbodiimides.
- thermoplastic synthetic polymer such as polylactides/glycolides co-formulated in the adhesive increases strength and provides a multiphased structure to the heat activated adhesive.
- the physical properties of such polymers may be selected or tailored by molecular weight, copolymer content, and plasticizer content.
- thermoplastic degradable polymers such as polylactides, polyglycolides and glycolide/lactide copolymers, and lactone polymers may be coated or covalently grafted to the surface of a protein microsphere, with the resulting microspheres having thermal bonding properties.
- Additional material stability can be achieved by the use of a heat activatable crosslinking component, such as a difunctional epoxide.
- a heat activatable crosslinking component such as a difunctional epoxide.
- Suitable chemical forms include diepoxide functional polyethylene glycols and polypropylene glycols, with activation occurring at temperatures ranging from room temperature to approximately 100 degrees C while demonstrating suitable toxicology.
- Another method of activation is the use of light initiated polymerization of co-formulated monomers or activatable crosslinkers.
- the activatable crosslinkers are chemically grafted to the surface of the biodegradable microparticles to promote high material integrity.
- Acrylate chemical functionality may be grafted onto gelatin microspheres for light activated polymerization of a particle bridging component such as acrylate and vinyl terminated polymers.
- An illustration of surface bridged particles is shown in FIG. 1.
- FIG. 2 Another method of activation is the mechanical disruption of hollow microspheres to allow mixing of reactive components.
- FIG. 2 An illustration of such a method is shown in FIG. 2.
- fibrinogen and factor XIII formulations form a useful surgical adhesive system, although with intensive preparation required and short working time.
- the encapsulation of the fibrinogen in a biodegradable polymer shell and formulation with a factor XIII containing solution provides a formulation readily applied with a catheter incorporating a mechanical disruption/mixing tip.
- Upon dispensing there is initiation of the fibrin adhesive to form a cohesive material. Materials having more rapid setting kinetics may be used since working time is short.
- a fibrin based adhesive incorporates at least 80 units of factor XIII activity per gram of fibrinogen and small amounts of plasminogen activator inhibitor to aid shelf life and extend working time, and protease inhibitor to increase in-situ residence time. With the encapsulation of either the factor XIII or the fibrinogen monomer, or both, a one component activatable biological adhesive is produced.
- a combination of a synthetic polymerization initiator and monomer may be sequestered into microencapsulated materials for activation upon mechanical disruption and mixing.
- examples include polyethylene glycol, polyethylene glycol/lactide or glycolide copolymers, reacted with polyethylene glycol diisocyanate, or other reactive difunctional agents.
- Cyanoacrylate monomer may be microencapsulated to prevent the initiation of polymerization by water until delivered at the catheter tip, thereby preventing setting and blockage in the catheter lumen.
- rapidly degradable microparticles may be incorporated into the adhesive. Upon degradation of such microparticles channels or pores will be formed which are beneficial for tissue in-growth. An illustration of an adhesive with such channels is shown in FIG. 3.
- the activation of the microparticulate adhesive can be performed at the surgical repair site by first dispensing the adhesive and then activating it with either light, heat, radio frequency, or other form of energy.
- a catheter with an activation mechanism at the tip is preferred.
- a concentric heating element around the catheter tip provides activation that can be coordinated with the feeding of the microparticles to dispense an activated adhesive.
- small gear mechanisms, rotating blades, or narrow orifices provide suitable mechanical shear for activation.
- Small ultrasonic transducers may be incorporated into a catheter, providing both mechanical and thermal energy to both rupture microcapsules and thermally activate the material.
- a fiber optic incorporated into the catheter tip may provide suitable adhesive activation at the dispensing tip.
- Biopolymer microcapsules were prepared containing dyed mineral oil by means of complex coacervation using the sodium salt of hyaluronic acid as the anionic polymer.
- the ratio of ingredients were as follows: gelatin, type A, 200 bloom 6 parts by wt hyaluronic acid, sodium salt 1 part water 100 parts mineral oil, dyed 25 parts
- Aqueous dispersions of the polymers were prepared, mixed together and adjusted to pH of 6.75 while heating to 36 degrees C. After emulsification of the mineral oil into the dispersion, the pH was slowly adjusted to 4.80 to stabilize the microcapsules. The resulting oil-containing microcapsules were retrieved by filtration and converted to a free flowing powder by solvent exchange with isopropyl alcohol with subsequent lyophilization.
- the pre-reactant component consisted of an aqueous slurry prepared at approximately 20% by weight and adjusted to a basic pH. Microscopic examination of the slurry revealed discrete multicore microcapsules uniformly dispersed in a water medium. The slurry was fed to the delivery site by a syringe pump and activated at the tip of the assembly through a heated nozzle. The nozzle consisted of a brass tube spirally wrapped with heater wire, all under a layer of fiberglass insulation. The nozzle temperature was adjusted by a Variac power controller applied to the heater coil. The slurry was pumped at approximately 20 ml/min, and heated to approximately 85 degrees C. Microscopic examination of the resulting material revealed that the microcapsules had ruptured and dissolved, releasing the oil contents from the protective gelatin shell.
- Gelatin microcapsules containing dyed mineral oil as previously described were prepared in accordance with the first example.
- a 20% aqueous slurry was prepared and adjusted to a basic pH.
- the slurry was sonicated at a setting of 5 for approximately 40 seconds. Microscopic examination of the resulting mixture revealed that the encapsulated oil had been released from the ruptured polymer capsules.
- Fibrinogen microspheres are prepared by coacervation of an aqueous dispersion emulsified into mineral oil. Slow dehydration with the addition of cold isopropyl alcohol yields a fibrinogen microsphere preparation of approximately 50 micron diameter. The resulting particles are isolated by centrifugation and washed in isopropyl alcohol and dried under vacuum. The free flowing particles are then encapsulated with a light coating of polylactic acid by spray drying. The particles are suspended in a methylene chloride dispersion of polylactic acid, in the range of 0.05 to 50 weight percent. The lower concentrations are preferred to form a thin encapsulating shell.
- the resulting coated microspheres are then formulated into a 30 weight percent slurry with phosphate buffer with thrombin or Factor XIII activity in the ratio of approximately 100 to 1000 units of Factor XIII activity per gram of encapsulated fibrinogen.
- the fibrinogen Upon passage of the flowable slurry through a catheter with a mechanical shearing tip, the fibrinogen is released and forms a cohesive gel-like material upon reaction with the thrombin.
- a flowable gelatin slurry was prepared by first mixing polyethylene glycol 400, glycerol, and water in the following proportions: polyethylene glycol 400 0.75 grams glycerol 2.25 grams water 1.00 grams
- a gelatin adhesive formulation was prepared with the following components: gelatin microspheres, ⁇ 25 to 50 micron diameter 250 mg polyethylene glycol, dialdehyde, 3400 MW 50 mg deionized water 2 grams
- a gelatin adhesive formulation was prepared with the following components: gelatin powder, grain size ⁇ 500 microns 9 grams polyethylene glycol 400 2.25 grams glycerol 7.5 grams polyethylene glycol, diepoxide, MW3400 200 mg
- Hollow gelatin microspheres were prepared by fabricating ⁇ 50 micron diameter gelatin microspheres by emulsion of a 200 bloom gelatin dispersion into mineral oil. The microspheres were recovered after precipitation with cold isopropanol and surface crosslinked in a mixture of 1,3 dimethylaminopropyl-3-ethylcarbodiimide hydrochloride at 0.67 mg/ml in 1:14 volume ratio of water:acetone for 12 minutes at room temperature. The microsphere crosslinking was quenched with a chilled, acidified water:acetone solution, and washed two time by centrifugation in acetone.
- microspheres were resuspended in deionized water and heated to 80 degrees C for 4 hours, after which the microspheres were isolated by centrifugation. Approximately 21% of the original gelatin weight was remaining, indicating an extraction of the uncrosslinked center. The resulting microspheres demonstrated a hollow morphology with very thin walls when examined microscopically.
- the gelatin microspheres were then washed in THF and grafted with caprolactone to form a thermoplastic polycaprolactone coating, covalently attached to the microsphere surface. Approximately 50 mg of the dried microspheres were placed in a reaction mixture containing the following components: 0.2 ml triethyl aluminum, 50% in toluene 2.0 grams caprolactone monomer 8.0 grams tetrahydrofurane
- the reaction was heated for approximately 5 hours at 40 degrees C.
- the microspheres were isolated from the reaction mixture by centrifugation at 2400 rpm for 15 minutes.
- the microspheres were washed 3 times in fresh THF solvent and recovered as dry, free flowing particles.
- the particles fused into a mass of aggregated microspheres. Under microscopy, the fused mass of material showed a reticulated morphology.
- a polymer dispersion of polycaprolactone (Solvay CAPA 650), 7.2 g in 30 ml of methylene chloride was prepared.
- a finely divided emulsion was formed by mixing the two immiscible solutions together with vigorous mixing. The viscous mixture was then poured on a glass plate, heated to 80 degrees C on a glass plate and allowed to dry at room temperature overnight. The material was then heated to 80 degrees C to form a melt, and molded into cylindrical shapes approximately 8.5 cm long and 0.65 cm in diameter.
- the resulting flexible rod was then melted and extruded through a heating tube of 0.2 cm diameter and heated to approximately 140 degrees centigrade.
- a molten polymer was dispensed which cooled into a very cohesive, flexible material with an appearance similar to the starting material.
- a 0.134 g specimen of the dispensed adhesive was placed in deionized water at 40 degrees C for approximately 64 hours to simulate extraction of the gelatin particle component in-vivo. The specimen was then removed and allowed to dry.
- the weight of the specimen was 0.064 g, a reduction of approximately one half of the weight, which roughly corresponds to the gelatin and glycerol/PEG components.
- the specimen had become white, the color of the caprolactone polymer. Microscopic inspection of the sample showed that the gelatin had been dissolved to form a surface porosity, with both interconnected and non-interconnected pores through the material cross-section.
Abstract
Flowable polymeric microparticulate surgical adhesive formulations are provided which can be activated at the site of the repair to produce cohesive material with tissue bonding properties to adjacent tissues. The formulation may be activated at the site of repair by mechanical shear forces, heat, ultrasound, UV, or other site.
Description
- The invention relates to surgical adhesives, and in particular to adhesives which are formed by combination or reaction of their components (hereinafter, “activated”) at the wound site.
- Surgical adhesives have long been of interest for reconstructing tissues due to the ease of applicability and combined mechanical securement and sealing function. Early use of a fibrin based adhesive, while totally biodegradable, was compromised by poor adhesive strength especially over time as enzyme degradation rapidly depolymerized the fibrin. Modern forms of fibrin adhesives incorporate enzyme inhibitors not only for practical workability, but to retard in-vivo degradation and loss of strength as described in U.S. Pat. No. 4,298,598. Still, these fibrin adhesives require the mixing of two components with long reconstitution times and demonstrate limited and variable working time before setting. In addition, the use of human pooled blood in these products has raised concern regarding potential viral contamination and transmission.
- Synthetic adhesive systems, such as the cyanoacrylates and cyanobutylates have high adhesive strength, but have poor degradation properties, with toxic byproducts such as formaldehyde being formed. Further, these materials are mechanically stiff and have poor integration properties with healing tissues. The cyanoacrylate type adhesive systems incorporate almost pure monomer which is initiated by water to form a high strength polymer. The rapidly setting adhesive is difficult to apply in some cases, especially in endoscopic use where the adhesive can set within the catheter lumen. Synthetic prepolymer approaches such as described in U.S. Pat. No. 4,804,691 may utilize biodegradable polymer components, but often rely on toxic components such as isocyanates and metal catalysts. Small amounts of toxicity may have adverse effect on the critical tissue to adhesive interface of a surgical adhesive.
- Collagen and gelatin based adhesive solutions have been investigated. Early clinical work with the gelatin-resorcinol-formaldehyde adhesive showed problems with tissue compatibility to the chemical agents and the cumbersome preparation of the adhesive. The use of a more toxicologically compatible collagen solution as described in EPA 0466383A1 requires heating of a collagen solution to partially transform it to gelatin. When applied heated onto the tissues, the material cools to form a bond. In this case the adhesive is only held together by chain entanglement of the collagen/gelatin chains, providing limited mechanical strength which is easily disrupted during subsequent hydration and enzymatic action. Stability of the adhesive material at higher solids content was a performance limitation.
- A method described in U.S. Pat. No. 5,156,613 describes the use of a solid collagen filler material which is applied to tissues while an energy source heats both the tissues and the filler material as a tissue welding aid. The denaturation of the tissues and filler, upon cooling provides a mechanical bond. While the approach utilizes high solids content adhesive, essentially a solid, the resultant adhesive material is held together by chain entanglement of the collagen/gelatin chains, limiting mechanical strength and biodegradation resistance. In addition, the inherent damage to underlying tissues of tissue welding approaches in general may prevent use on or near sensitive tissues such as fragile vasculature, nervous tissue, ocular tissue, and areas of cosmetic concern such as the face and neck. A similar approach is described in U.S. Pat. No. 5,209,776 where peptides such as collagen and albumin are mixed with either a polysaccharide or polyalcohol to form a viscous solution which can be used as a sealant or coating. As the coating has no material integrity, it is a weak flowable gel as described, with the primary utility as a adjuvant to tissue welding techniques.
- The present invention describes novel tissue adhesives comprising a flowable polymeric microparticulate formulation which can be site activated to produce a cohesive material with tissue bonding properties to adjacent tissues. When activated, the material can be used to join tissues, seal tissue junctions, act as an injectable embolization agent, augment tissues and reinforce organ walls. The use of microparticulates allows facile applicability as a powder or paste to tissues, with the microparticles able to flow into the tissue crevices and set into the appropriate conformation.
- It is an object of the invention to provide a high solids content surgical adhesive which provides total biodegradability, high mechanical integrity, and activation at the delivery site or wound, which alleviates the problem of delay of application after mixing reactive components.
- Further objects are to provide a formulation for flowable systems, to prevent damage to contacting tissues during application of the adhesive and biodegradation, to control the degradation rate of the adhesive, and to provide tissue ingrowth features in an adhesive to provide a gradual load transfer to the healing tissues.
- FIG. 1 shows the activation of the surface of microparticles to form a solid material by polymer bridging.
- FIG. 2 shows the activation of a polymerization mechanism by the mixing of encapsulated reagents A and B to form a product C.
- FIG. 3 shows the formation of a material with channels formed by activation of a particulate polymer composition.
- FIG. 4 shows activation of a flowable microparticulate formulation at the tip of a catheter with heat generating elements, D, to deliver a molten polymer adhesive.
- FIG. 5 shows activation of a flowable microcapsule formulation at the tip of a catheter with a rotating outer shaft, E, to spin a rotor, F, in the flow path to mechanically disrupt the microcapsules and deliver an initiated adhesive.
- The microparticulate adhesive comprises biodegradable components to allow for natural degradation and progressive incorporation with newly formed tissue. This is particularly important for the clinical success of a surgical adhesive as rapid mechanical failure of the adhesive may lead to clinical problems. Preferred components are biodegradable polymers including biopolymers such as collagen, gelatin, elastin, hyaluronic acid, and fibrin; synthetic degradable polymers such as poly lactic/glycolic acid polymers and copolymers, polyhydroxybuterate, and polycaprolactone; and biological polymerization components such as fibrinogen and factor XIII.
- Biopolymers such as collagen and gelatin in particular provide a progressive degradation and load transfer to the healing tissues which would be preferred for clinical efficacy. The tissue integration of the surgical adhesive with the healing tissues may be further promoted by the formation of a porous structure by the microspheres in-situ, thereby allowing tissue ingrowth and mechanical interlocking. Other components, such as growth factors and chemotactic agents, may also be incorporated into the adhesive to further increase tissue incorporation and the performance of the tissue repair.
- The use of insoluble microparticles in a solvent mixture greatly reduces viscosity and allows the use of a very high solids content formulation that is flowable. For example, a typical collagen or gelatin composition can achieve solids contents up to approximately 10 to 20 weight % before the viscosity of the polymer increases to form a non-flowable solid. By constraining the polymer into discreet, insoluble microparticles and preventing full polymer mobility, flowable solids contents of approximately 50 weight % can be achieved. Since the solvent vehicle in a polymeric adhesive, such as water, does not participate in forming a structural adhesive, it is important to maximize the amount of structural polymer that is delivered as an adhesive. Small amounts of reactive adhesive components or flow enhancers, may be incorporated into the solvent vehicle for the microparticles, especially if they are of lower molecular weight to prevent viscosity limitations.
- The use of microparticles or microspheres not only allows high solids content, flowable formulations, but also allows activatable components to be packaged within hollow or surface coated constructs similar to industrial one part adhesives. While the typical encapsulation of a catalyst in an industrial one-part adhesive utilizes rigid, fracturable materials such as glass, silica, and rigid thermoplastics to enhance rupture efficiency, these types of materials are not toxicologically acceptable for implantation in tissues. The present invention utilizes microcapsules fabricated entirely from biodegradable polymers that can are rupturable by careful control of capsule thickness, and, optionally, by use of chemical surface stabilization. In one embodiment, hollow microspheres or microcapsules are fabricated from biodegradable materials and packed with reactive components such as synthetic or biological polymerization systems. The reactive components may be isolated in discreet capsules, which polymerize to form an adhesive when the capsules are broken by mechanical shear and mixed, such as at the end of a delivery catheter. An illustration of this method is shown in FIG. 5. An example is the packaging of fibrinogen in microcapsules with separate microcapsules of thrombin. Upon mechanical rupture, the components react to form a fibrin adhesive. Similarly, reactive adhesive components may be packaged within water insoluble capsules and delivered in an non-aqueous solvent to be activated in situ by hydration. Thus, by activation of the adhesive at a catheter tip at the tissue site, working time and pot life considerations are minimized and adhesive kinetics and ultimate properties can be optimized.
- Activation methods other than mechanical shear can be utilized with the microcapsules or microparticles. Heat can be used to flow and/or rupture the particles by tailoring the thermal transition properties of the particulate materials. An illustration of that method is shown in FIG. 4. Both biopolymers and biodegradable synthetic polymers have thermal transitions such as the glass transition temperature, which can be tailored for use as adhesive microparticles. Physical methods such as ultrasound can be used in a combined mechanical/thermal activation method. Radio frequency and microwave excitation, while having some patient shielding concerns, may also be utilized to thermally activate or rupture the microparticles to initiate the adhesive.
- It is important that the activation of the microparticles trigger reactions which form physiologically stable linkages within the resultant material. Typical linkages used include covalent crosslinks either formed chemically or enzymatically, strong ionic interactions such as chelation, strong hydrophobic interactions, or inter-chain entanglement of polymers. For high physical strength, covalent crosslinking and/or chain entanglement are preferred. In the case of chain entanglement alone, such as the application of a heat activatable thermoplastic polymer component, it is important that the glass transition of the polymer be above physiological temperature to form a stable material. Otherwise, the resultant material would lack material integrity within the body, as occurs with non-crosslinked gelatin, for example, with a transition temperature of about 37° centigrade.
- Besides rupturing the microparticles to release adhesive components, the particles themselves may physically participate in the adhesive material. The microparticles or microcapsules are fabricated from high strength degradable polymers with affinity for the adhesive components. In a system where microcapsules are ruptured to mix and initiate a chemical adhesive, the wall components will be incorporated into the final adhesive material, acting as particulate reinforcements, similar to glass filled polymers. The same structural properties which allow the microcapsule to resist premature rupture during use can be further tailored to provide structural reinforcement of the adhesive material, especially controllable by crosslinking the capsule material for the proper biodegradation rate.
- In some cases, it may not be necessary or desired to rupture the microparticles. By combining the microparticles with a flowable component which can be set into a solid, or by activating the surface of the microparticles, polymer bridges between particles may be formed to provide structural material from the joined particles, similar to a sintered polymer. Suitable activation methods may be used, such as heat to activate a thermoplastic polymer component or coating of the microparticles. Other particle bridging components include collagen and gelatin, which will flow upon controlled heating and can be further enhanced by a thermoplastic coating or chemical surface graft such as polylactic/glycolic acid polymers. As a bridging component, non-encapsulated polymer or reactive components such as difunctional epoxides reagents may be used to facilitate adhesive setting. Other particle bridging methods include optically activatable groups such as acrylate functional materials which may be incorporated onto the microparticles or formulated as a non-encapsulated component.
- When significant portions of microparticles remain at least partially intact, the formation of channels of microparticles occur in the material. Degradable microparticles may be used which to rapidly degrade and form a porous network during biodegradation allowing tissue ingrowth and progressive load transfer to the healing tissues, which is ideal for preventing failure of the surgical adhesive repair.
- The degradable microparticles may be fabricated by many available methods. Dry materials can be pulverized and sieved to produce irregular solid particles of selected size range. Irregular particles, while simple to fabricate, tend to pack and clog during flow at high solids contents. Microspheres, with a smooth outer surface have less tendency to interlock with other particles, allowing for increased solids content of a flowable formulation. Microspheres can be fabricated by a variety of method including spray drying, coacervation/emulsion methods, and droplet coagulation. In a preferred method for making hollow microspheres, a limited amount of cross-linking agent can be applied to solid microspheres, then the cross-linking reaction is quenched. The uncrosslinked centers may be extracted with a suitable solvent which swells the cross-linked shell and dissolves the uncrosslinked centers.
- Polymers in particular lend themselves to microsphere fabrication. Polymeric microspheres may be further tailored after fabrication by chemical crosslinking to control solubility and biodegradation properties, and also chemically grafted or coated for chemical activation. Microspheres with hollow cavities may be used to isolate reactive adhesive components. Such microcapsules may be formed with single or multiple cavities by methods such as interfacial deposition, spray drying over a removable core, and the like. To package the reactive components, they may be formed into particles and coated during fabrication into microspheres. Alternatively, some reactive components of low molecular weight may be incorporated by swelling the prefabricated microcapsules with a solution of the component and allowing for diffusion into the microcapsule interior.
- It is preferred that the biodegradable microparticles have an activatable mechanism to allow in-situ formation of a cohesive material. Heat can be used to fuse the microparticulate surfaces together with the degree controlled by the microparticle surface composition and thermal transition properties. In one method, gelatin particles are fused together to form a cohesive mass upon heating at the end of a catheter tip. The gelatin thermal transition may be altered by the selection of the gelatin molecular weight, degree of deamidation, the type and extent of side chain modifications, and the degree of chemical crosslinking with difunctional chemical agents such as dialdehydes and diisocyanates or peptide crosslinking agents such as carbodiimides. Less crosslinked materials show lower temperatures needed for flowing of the particulates into a cohesive mass. The use of a thermoplastic synthetic polymer such as polylactides/glycolides co-formulated in the adhesive increases strength and provides a multiphased structure to the heat activated adhesive. The physical properties of such polymers may be selected or tailored by molecular weight, copolymer content, and plasticizer content. In one embodiment, thermoplastic degradable polymers such as polylactides, polyglycolides and glycolide/lactide copolymers, and lactone polymers may be coated or covalently grafted to the surface of a protein microsphere, with the resulting microspheres having thermal bonding properties. Additional material stability can be achieved by the use of a heat activatable crosslinking component, such as a difunctional epoxide. Suitable chemical forms include diepoxide functional polyethylene glycols and polypropylene glycols, with activation occurring at temperatures ranging from room temperature to approximately 100 degrees C while demonstrating suitable toxicology.
- Another method of activation is the use of light initiated polymerization of co-formulated monomers or activatable crosslinkers. In one embodiment, the activatable crosslinkers are chemically grafted to the surface of the biodegradable microparticles to promote high material integrity. Acrylate chemical functionality may be grafted onto gelatin microspheres for light activated polymerization of a particle bridging component such as acrylate and vinyl terminated polymers. An illustration of surface bridged particles is shown in FIG. 1.
- Another method of activation is the mechanical disruption of hollow microspheres to allow mixing of reactive components. An illustration of such a method is shown in FIG. 2. For a biological adhesive, for example, fibrinogen and factor XIII formulations form a useful surgical adhesive system, although with intensive preparation required and short working time. However, the encapsulation of the fibrinogen in a biodegradable polymer shell and formulation with a factor XIII containing solution provides a formulation readily applied with a catheter incorporating a mechanical disruption/mixing tip. Upon dispensing, there is initiation of the fibrin adhesive to form a cohesive material. Materials having more rapid setting kinetics may be used since working time is short. Typically, a fibrin based adhesive incorporates at least 80 units of factor XIII activity per gram of fibrinogen and small amounts of plasminogen activator inhibitor to aid shelf life and extend working time, and protease inhibitor to increase in-situ residence time. With the encapsulation of either the factor XIII or the fibrinogen monomer, or both, a one component activatable biological adhesive is produced.
- Similarly, a combination of a synthetic polymerization initiator and monomer may be sequestered into microencapsulated materials for activation upon mechanical disruption and mixing. Examples include polyethylene glycol, polyethylene glycol/lactide or glycolide copolymers, reacted with polyethylene glycol diisocyanate, or other reactive difunctional agents. Cyanoacrylate monomer may be microencapsulated to prevent the initiation of polymerization by water until delivered at the catheter tip, thereby preventing setting and blockage in the catheter lumen.
- Furthermore, rapidly degradable microparticles may be incorporated into the adhesive. Upon degradation of such microparticles channels or pores will be formed which are beneficial for tissue in-growth. An illustration of an adhesive with such channels is shown in FIG. 3.
- The activation of the microparticulate adhesive can be performed at the surgical repair site by first dispensing the adhesive and then activating it with either light, heat, radio frequency, or other form of energy. For endoscopic use, a catheter with an activation mechanism at the tip is preferred. A concentric heating element around the catheter tip provides activation that can be coordinated with the feeding of the microparticles to dispense an activated adhesive. Similarly, for reactive adhesive systems where microcapsules are ruptured and mixed, small gear mechanisms, rotating blades, or narrow orifices provide suitable mechanical shear for activation. Small ultrasonic transducers may be incorporated into a catheter, providing both mechanical and thermal energy to both rupture microcapsules and thermally activate the material. Similarly, for optical systems, a fiber optic incorporated into the catheter tip may provide suitable adhesive activation at the dispensing tip.
- Gelatin/Hyaluronic Acid Microcapsules Activated by Heat
- Biopolymer microcapsules were prepared containing dyed mineral oil by means of complex coacervation using the sodium salt of hyaluronic acid as the anionic polymer. The ratio of ingredients were as follows:
gelatin, type A, 200 bloom 6 parts by wt hyaluronic acid, sodium salt 1 part water 100 parts mineral oil, dyed 25 parts - Aqueous dispersions of the polymers were prepared, mixed together and adjusted to pH of 6.75 while heating to 36 degrees C. After emulsification of the mineral oil into the dispersion, the pH was slowly adjusted to 4.80 to stabilize the microcapsules. The resulting oil-containing microcapsules were retrieved by filtration and converted to a free flowing powder by solvent exchange with isopropyl alcohol with subsequent lyophilization.
- The dyed mineral oil contained within the microspheres thus serving as an active agent analog, the pre-reactant component consisted of an aqueous slurry prepared at approximately 20% by weight and adjusted to a basic pH. Microscopic examination of the slurry revealed discrete multicore microcapsules uniformly dispersed in a water medium. The slurry was fed to the delivery site by a syringe pump and activated at the tip of the assembly through a heated nozzle. The nozzle consisted of a brass tube spirally wrapped with heater wire, all under a layer of fiberglass insulation. The nozzle temperature was adjusted by a Variac power controller applied to the heater coil. The slurry was pumped at approximately 20 ml/min, and heated to approximately 85 degrees C. Microscopic examination of the resulting material revealed that the microcapsules had ruptured and dissolved, releasing the oil contents from the protective gelatin shell.
- Gelatin/Hyaluronic Acid Microcapsules Activated by Ultrasound
- Gelatin microcapsules containing dyed mineral oil as previously described were prepared in accordance with the first example. A 20% aqueous slurry was prepared and adjusted to a basic pH. Using a Heat Systems model 2020XL ultrasonic generator with standard probe and microtip horn, the slurry was sonicated at a setting of 5 for approximately 40 seconds. Microscopic examination of the resulting mixture revealed that the encapsulated oil had been released from the ruptured polymer capsules.
- Thrombin Based Adhesive Utilizing Encapsulated Fibrinogen Activated Mechanically
- Fibrinogen microspheres are prepared by coacervation of an aqueous dispersion emulsified into mineral oil. Slow dehydration with the addition of cold isopropyl alcohol yields a fibrinogen microsphere preparation of approximately 50 micron diameter. The resulting particles are isolated by centrifugation and washed in isopropyl alcohol and dried under vacuum. The free flowing particles are then encapsulated with a light coating of polylactic acid by spray drying. The particles are suspended in a methylene chloride dispersion of polylactic acid, in the range of 0.05 to 50 weight percent. The lower concentrations are preferred to form a thin encapsulating shell. The resulting coated microspheres are then formulated into a 30 weight percent slurry with phosphate buffer with thrombin or Factor XIII activity in the ratio of approximately 100 to 1000 units of Factor XIII activity per gram of encapsulated fibrinogen. Upon passage of the flowable slurry through a catheter with a mechanical shearing tip, the fibrinogen is released and forms a cohesive gel-like material upon reaction with the thrombin.
- Gelatin Particulate Based Adhesive Formulation Activated by Heat
- A flowable gelatin slurry was prepared by first mixing polyethylene glycol 400, glycerol, and water in the following proportions:
polyethylene glycol 400 0.75 grams glycerol 2.25 grams water 1.00 grams - To this solution was added 3 grams of gelatin powder having a grain size no greater than approximately 500 microns to form a 40 weight percent solids slurry. The slurry was fed to the delivery site using the nozzle system described in the first example. The slurry was pumped at approximately 3 ml/min and heated to approximately 100 degrees C. Exiting the nozzle was a highly viscous, molten gelatin. Upon cooling the material hardened into a cohesive rubbery mass.
- Gelatin Microsphere Based Adhesive Formulation with In-Situ Crosslinking
- A gelatin adhesive formulation was prepared with the following components:
gelatin microspheres, ˜25 to 50 micron diameter 250 mg polyethylene glycol, dialdehyde, 3400 MW 50 mg deionized water 2 grams - The mixture was quickly mixed and allowed to set at room temperature. After one half hour, the material has become a firm gel. Incubation at 45 degrees C showed a stable gel, unlike the non-crosslinked control sample which dissolved. Microscopic examination showed a cohesive mass of microspheres, bridged together to form the material.
- Gelatin Particulate Based Adhesive Formulation with Heat Activated Crosslinking
- A gelatin adhesive formulation was prepared with the following components:
gelatin powder, grain size < 500 microns 9 grams polyethylene glycol 400 2.25 grams glycerol 7.5 grams polyethylene glycol, diepoxide, MW3400 200 mg - The components were stirred together to form a particulate slurry of approximately 47 weight % solids. With a syringe, the mixture was extruded through a heating element with a 0.5 cm bore, heated to approximately 140 degrees C. The extrudate was a uniform transparent amber color, indicating fusion of the gelatin material. Once cooled, the material exhibited a cohesive, rubbery properties. The material was stable when placed in water heated to 40 degrees C for 17 hours, indicating crosslinking into a stable adhesive material.
- Hollow Gelatin Microsphere with Thermoplastic Polymer Graft Based Adhesive Formulation. Activated by Heat
- Hollow gelatin microspheres were prepared by fabricating ˜50 micron diameter gelatin microspheres by emulsion of a 200 bloom gelatin dispersion into mineral oil. The microspheres were recovered after precipitation with cold isopropanol and surface crosslinked in a mixture of 1,3 dimethylaminopropyl-3-ethylcarbodiimide hydrochloride at 0.67 mg/ml in 1:14 volume ratio of water:acetone for 12 minutes at room temperature. The microsphere crosslinking was quenched with a chilled, acidified water:acetone solution, and washed two time by centrifugation in acetone. The microspheres were resuspended in deionized water and heated to 80 degrees C for 4 hours, after which the microspheres were isolated by centrifugation. Approximately 21% of the original gelatin weight was remaining, indicating an extraction of the uncrosslinked center. The resulting microspheres demonstrated a hollow morphology with very thin walls when examined microscopically. The gelatin microspheres were then washed in THF and grafted with caprolactone to form a thermoplastic polycaprolactone coating, covalently attached to the microsphere surface. Approximately 50 mg of the dried microspheres were placed in a reaction mixture containing the following components:
0.2 ml triethyl aluminum, 50% in toluene 2.0 grams caprolactone monomer 8.0 grams tetrahydrofurane - The reaction was heated for approximately 5 hours at 40 degrees C. The microspheres were isolated from the reaction mixture by centrifugation at 2400 rpm for 15 minutes. The microspheres were washed 3 times in fresh THF solvent and recovered as dry, free flowing particles. When heated on a glass slide at approximately 90 degrees C, the particles fused into a mass of aggregated microspheres. Under microscopy, the fused mass of material showed a reticulated morphology.
- Gelatin Particulate Based Adhesive with Thermoplastic Binding Agent
- A polymer dispersion of polycaprolactone (Solvay CAPA 650), 7.2 g in 30 ml of methylene chloride was prepared. A separate dispersion of gelatin, 4.8 g of gelatin was dissolved with light heating into 11.2 ml of deionized water containing 1.6 g each of glycerol and PEG 400. A finely divided emulsion was formed by mixing the two immiscible solutions together with vigorous mixing. The viscous mixture was then poured on a glass plate, heated to 80 degrees C on a glass plate and allowed to dry at room temperature overnight. The material was then heated to 80 degrees C to form a melt, and molded into cylindrical shapes approximately 8.5 cm long and 0.65 cm in diameter. The resulting flexible rod was then melted and extruded through a heating tube of 0.2 cm diameter and heated to approximately 140 degrees centigrade. A molten polymer was dispensed which cooled into a very cohesive, flexible material with an appearance similar to the starting material. A 0.134 g specimen of the dispensed adhesive was placed in deionized water at 40 degrees C for approximately 64 hours to simulate extraction of the gelatin particle component in-vivo. The specimen was then removed and allowed to dry. The weight of the specimen was 0.064 g, a reduction of approximately one half of the weight, which roughly corresponds to the gelatin and glycerol/PEG components. The specimen had become white, the color of the caprolactone polymer. Microscopic inspection of the sample showed that the gelatin had been dissolved to form a surface porosity, with both interconnected and non-interconnected pores through the material cross-section.
Claims (25)
1. A microparticulate surgical adhesive composition comprising biodegradable polymeric microparticles; which are activatable in-situ to form a high strength, cohesive material which is physiologically stable.
2. An adhesive composition according to which is activatable in-situ by rupturing of an impermeable outer shell or coating of said microparticles to initiate a chemical reaction to form said cohesive material.
claim 1
3. An adhesive composition according to which is activatable in-situ by fusion of said microparticles to form said cohesive material.
claim 1
4. An adhesive composition according to which is activatable in-situ to form said cohesive material which comprise channels or pores for tissue integration.
claim 1
5. An adhesive composition according to comprising a flowable slurry with a physiologically compatible solvent.
claim 1
6. An adhesive composition according to which is activatable by heat.
claim 1
7. An adhesive composition according to which is activatable by ultrasound energy.
claim 1
8. An adhesive composition according to which is activatable by radio frequency or microwave energy.
claim 1
9. An adhesive composition according to which is activatable by light.
claim 1
10. An adhesive composition according to which is activatable by mechanical shear.
claim 1
11. An adhesive composition according to which further comprises a particle bridging component.
claim 1
12. An adhesive composition according to which further comprises a coating or chemical graft on the surfaces of said microparticles.
claim 1
13. An adhesive composition according to which further comprises modified chemical surfaces of the microparticles.
claim 1
14. An adhesive composition according to which further comprises growth factors or chemotactic factors.
claim 1
15. An adhesive composition according to which further comprises wound healing agents, anti-infective agents or anti-inflammatory agents.
claim 1
16. An adhesive composition according to which further comprises hollow microparticles.
claim 1
17. An adhesive composition according to which further comprises coated components which are ruptured to initiate formation of adhesive.
claim 1
18. An adhesive composition according to which further comprises collagen or gelatin microparticles.
claim 1
19. An adhesive composition according to which further comprises fibrinogen and factor XIII.
claim 1
20. An adhesive composition according to which further comprises a biodegradable thermoplastic polymer.
claim 1
21. A flowable adhesive composition according to having a solids content greater than 20 weight percent.
claim 1
22. A method for the securement and sealing of tissue by the site activation of a biodegradable microparticle composition comprising biodegradable polymeric microparticles, which are activatable in-situ to form a high strength, cohesive material which is physiologically stable.
23. A method for the securement and sealing of tissue by the introduction of a microparticle composition comprising biodegradable polymeric microparticles, which are activatable in-situ to form a high strength, cohesive material which is physiologically stable through an apparatus which activates said composition as it is delivered to the target tissues.
24. A method for the embolization of biological vessels by the introduction of a microparticle composition comprising biodegradable polymeric microparticles, which are activatable in-situ to form a high strength, cohesive material which is physiologically stable through a catheter which activates said composition as it is delivered to the target tissues.
25. A method for fabricating hollow microcapsules by the introduction of limited crosslinking agent to surfaces of microspheres, quenching the crosslinking reaction, and extracting the centers of the microspheres with a solvent which swells the crosslinked shell and allows extraction of the uncrosslinked centers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/352,615 US20010008636A1 (en) | 1996-04-25 | 1999-07-13 | Microparticulate surgical adhesive |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/639,285 US5948427A (en) | 1996-04-25 | 1996-04-25 | Microparticulate surgical adhesive |
US09/352,615 US20010008636A1 (en) | 1996-04-25 | 1999-07-13 | Microparticulate surgical adhesive |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/639,285 Division US5948427A (en) | 1996-04-25 | 1996-04-25 | Microparticulate surgical adhesive |
Publications (1)
Publication Number | Publication Date |
---|---|
US20010008636A1 true US20010008636A1 (en) | 2001-07-19 |
Family
ID=24563490
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/639,285 Expired - Fee Related US5948427A (en) | 1996-04-25 | 1996-04-25 | Microparticulate surgical adhesive |
US09/352,615 Abandoned US20010008636A1 (en) | 1996-04-25 | 1999-07-13 | Microparticulate surgical adhesive |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/639,285 Expired - Fee Related US5948427A (en) | 1996-04-25 | 1996-04-25 | Microparticulate surgical adhesive |
Country Status (1)
Country | Link |
---|---|
US (2) | US5948427A (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050163817A1 (en) * | 2002-04-29 | 2005-07-28 | Masters David B. | Biomatrix structural containment and fixation systems and methods of use thereof |
US20050196440A1 (en) * | 2003-12-08 | 2005-09-08 | Masters David B. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20060115805A1 (en) * | 2002-12-11 | 2006-06-01 | Hansen John E | Gelatine-based materials as swabs |
US20060167540A1 (en) * | 2003-06-17 | 2006-07-27 | Masters David B | Encapsulated or coated stent systems |
US20070009578A1 (en) * | 2004-07-09 | 2007-01-11 | Lene Moller | Haemostatic composition comprising hyaluronic acid |
US20070160543A1 (en) * | 2004-01-30 | 2007-07-12 | Lene Moller | Haemostatic sprays and compositions |
US20100143487A1 (en) * | 2007-12-26 | 2010-06-10 | Gel-Del Technologies, Inc. | Biocompatible protein-based particles and methods thereof |
US20100196478A1 (en) * | 1998-09-25 | 2010-08-05 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US20110021964A1 (en) * | 2008-02-29 | 2011-01-27 | Ferrosan Medical Devices A/S | Device for Promotion of Hemostasis and/or Wound Healing |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US8153591B2 (en) | 2003-08-26 | 2012-04-10 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10016534B2 (en) | 2008-11-17 | 2018-07-10 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
CN109561973A (en) * | 2016-08-17 | 2019-04-02 | 联合创新技术有限责任公司 | Fixation device for orthopaedic prosthesis, the annealing device and application method for orthopaedic prosthesis |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6323037B1 (en) * | 1998-04-06 | 2001-11-27 | Cornell Research Foundation, Inc. | Composition for tissue welding and method of use |
US20050171594A1 (en) * | 1998-12-31 | 2005-08-04 | Angiotech International Ag | Stent grafts with bioactive coatings |
US20020065546A1 (en) * | 1998-12-31 | 2002-05-30 | Machan Lindsay S. | Stent grafts with bioactive coatings |
US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
US7129300B2 (en) * | 2001-07-31 | 2006-10-31 | Tyco Healthcare Group Lp | Bioabsorbable adhesive compounds and compositions |
WO2003088844A1 (en) * | 2002-04-15 | 2003-10-30 | Cook Biotech Incorporated | Apparatus and method for producing a reinforced surgical staple line |
EP1581270A2 (en) * | 2002-12-30 | 2005-10-05 | Angiotech International Ag | Silk-containing stent graft |
US7658747B2 (en) | 2003-03-12 | 2010-02-09 | Nmt Medical, Inc. | Medical device for manipulation of a medical implant |
US7603179B1 (en) * | 2003-09-16 | 2009-10-13 | Boston Scientific Neuromodulation Corporation | System and method for lead fixation |
AU2004289362A1 (en) * | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Intravascular devices and fibrosis-inducing agents |
US20050175709A1 (en) * | 2003-12-11 | 2005-08-11 | Baty Ace M.Iii | Therapeutic microparticles |
US8262694B2 (en) | 2004-01-30 | 2012-09-11 | W.L. Gore & Associates, Inc. | Devices, systems, and methods for closure of cardiac openings |
EP1796747B1 (en) * | 2004-08-27 | 2017-07-05 | Antonio Lauto | Bioadhesve film for tissue repair |
WO2006101719A2 (en) * | 2005-03-18 | 2006-09-28 | Wilk Patent, Llc | Surgical device and associated trans-organ surgical method |
US20060241651A1 (en) * | 2005-04-22 | 2006-10-26 | Wilk Patent, Llc | Surgical port device and associated method |
US7753934B2 (en) * | 2005-04-22 | 2010-07-13 | Wilk Patent, Llc | Medical closure method and associated device |
EP1962867B1 (en) * | 2005-12-06 | 2013-06-19 | Covidien LP | Biocompatible surgical compositions |
WO2007067622A2 (en) * | 2005-12-06 | 2007-06-14 | Tyco Healthcare Group Lp | Carbodiimide crosslinking of functionalized polethylene glycols |
JP5485551B2 (en) | 2005-12-06 | 2014-05-07 | コヴィディエン リミテッド パートナーシップ | Bioabsorbable compounds and compositions containing them |
EP2633834A1 (en) * | 2005-12-06 | 2013-09-04 | Covidien LP | Bioabsorbable Surgical Composition |
JP5088894B2 (en) * | 2005-12-06 | 2012-12-05 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Biocompatible tissue sealant and adhesive |
CA2629932C (en) * | 2005-12-08 | 2014-07-08 | Tyco Healthcare Group Lp | Viscosity-reduced sprayable compositions |
JP2009518142A (en) * | 2005-12-08 | 2009-05-07 | タイコ ヘルスケア グループ リミテッド パートナーシップ | Biocompatible surgical composition |
CA2629936A1 (en) * | 2005-12-08 | 2007-06-14 | Tyco Healthcare Group Lp | Biocompatible surgical compositions |
US10507083B2 (en) * | 2006-12-28 | 2019-12-17 | Woodwelding Ag | Affixing an artificial element to a surface of dentine, enamel, bone, or a corresponding substitute material |
US9034367B2 (en) * | 2007-05-10 | 2015-05-19 | Cormatrix Cardiovascular, Inc. | Articles for tissue regeneration with biodegradable polymer |
WO2009002246A1 (en) * | 2007-06-26 | 2008-12-31 | Celltrix Ab | Stabilised porous structures, process for production thereof and use thereof |
WO2009020607A2 (en) * | 2007-08-07 | 2009-02-12 | Arsenal Medical, Inc. | Method and apparatus for composite drug delivery medical devices |
US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
CN101965211A (en) | 2008-03-05 | 2011-02-02 | 伊万提斯公司 | Methods and apparatus for treating glaucoma |
CA2745884C (en) | 2008-12-05 | 2017-08-01 | Ivantis, Inc. | Cannula for ocular implant delivery system |
EP2451375B1 (en) | 2009-07-09 | 2018-10-03 | Ivantis, Inc. | Single operator device for delivering an ocular implant |
EP2451503B1 (en) | 2009-07-09 | 2018-10-24 | Ivantis, Inc. | Ocular implants and methods for delivering ocular implants into the eye |
CN102647960A (en) | 2009-10-23 | 2012-08-22 | 伊万提斯公司 | Ocular implant system and method |
US8545430B2 (en) | 2010-06-09 | 2013-10-01 | Transcend Medical, Inc. | Expandable ocular devices |
US9510973B2 (en) | 2010-06-23 | 2016-12-06 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
US9044722B2 (en) | 2010-11-10 | 2015-06-02 | Darren Edward Nolen | Multi-component, temperature activated, tissue adhesive, sealing, and filling composition |
US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
US10617558B2 (en) | 2012-11-28 | 2020-04-14 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
US10010447B2 (en) | 2013-12-18 | 2018-07-03 | Novartis Ag | Systems and methods for subretinal delivery of therapeutic agents |
SG10201909098PA (en) * | 2014-03-28 | 2019-11-28 | Swiss Vx Venentherapie Und Forschung Gmbh | Compositions and devices for sclerotherapy using light hardening glues |
US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
EP4265231A3 (en) | 2015-08-14 | 2023-12-20 | Alcon Inc. | Ocular implant with pressure sensor |
WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
KR20230130622A (en) | 2021-01-11 | 2023-09-12 | 알콘 인코포레이티드 | Systems and methods for viscoelastic delivery |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2986477A (en) * | 1958-06-19 | 1961-05-30 | Ncr Co | Adhesive tape |
US3779942A (en) * | 1970-12-04 | 1973-12-18 | Minnesota Mining & Mfg | Capsules and process for forming capsules |
US4273672A (en) * | 1971-08-23 | 1981-06-16 | Champion International Corporation | Microencapsulation process |
US3886085A (en) * | 1971-08-31 | 1975-05-27 | Fuji Photo Film Co Ltd | Process for producing fine oil-containing microcapsules having strong protective shells and microcapsules produced thereby |
US3875074A (en) * | 1972-03-06 | 1975-04-01 | Champion Int Corp | Formation of microcapsules by interfacial cross-linking of emulsifier, and microcapsules produced thereby |
DE2710548C2 (en) * | 1977-03-10 | 1982-02-11 | Rudolf 8019 Moosach Hinterwaldner | Storage-stable hardenable composition and method for hardening it |
US4900303A (en) * | 1978-03-10 | 1990-02-13 | Lemelson Jerome H | Dispensing catheter and method |
AT359653B (en) * | 1979-02-15 | 1980-11-25 | Immuno Ag | METHOD FOR PRODUCING A TISSUE ADHESIVE |
US4940852A (en) * | 1986-07-16 | 1990-07-10 | Milton P. Chernack | Pressure sensitive adhesive composition |
US5225278A (en) * | 1987-08-26 | 1993-07-06 | Rohm And Haas Company | Process for microencapsulation |
US4804691A (en) * | 1987-08-28 | 1989-02-14 | Richards Medical Company | Method for making a biodegradable adhesive for soft living tissue |
AT397203B (en) * | 1988-05-31 | 1994-02-25 | Immuno Ag | FABRIC ADHESIVE |
US5045569A (en) * | 1988-11-30 | 1991-09-03 | Minnesota Mining And Manufacturing Company | Hollow acrylate polymer microspheres |
US5260071A (en) * | 1989-12-18 | 1993-11-09 | Lemelson Jerome H | Drug units and methods for using same |
EP0466383A1 (en) * | 1990-07-09 | 1992-01-15 | BAUSCH & LOMB INCORPORATED | A collagen medical adhesive and its uses |
US5209776A (en) * | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
US5219895A (en) * | 1991-01-29 | 1993-06-15 | Autogenesis Technologies, Inc. | Collagen-based adhesives and sealants and methods of preparation and use thereof |
US5156613A (en) * | 1991-02-13 | 1992-10-20 | Interface Biomedical Laboratories Corp. | Collagen welding rod material for use in tissue welding |
US5487895A (en) * | 1993-08-13 | 1996-01-30 | Vitaphore Corporation | Method for forming controlled release polymeric substrate |
GB2281861B (en) * | 1993-09-21 | 1997-08-20 | Johnson & Johnson Medical | Bioabsorbable wound implant materials containing microspheres |
-
1996
- 1996-04-25 US US08/639,285 patent/US5948427A/en not_active Expired - Fee Related
-
1999
- 1999-07-13 US US09/352,615 patent/US20010008636A1/en not_active Abandoned
Cited By (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871267B2 (en) | 1998-09-25 | 2014-10-28 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US20100196478A1 (en) * | 1998-09-25 | 2010-08-05 | Gel-Del Technologies, Inc. | Protein matrix materials, devices and methods of making and using thereof |
US8283320B2 (en) | 2001-12-21 | 2012-10-09 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostasis |
US7923431B2 (en) | 2001-12-21 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
US20050163817A1 (en) * | 2002-04-29 | 2005-07-28 | Masters David B. | Biomatrix structural containment and fixation systems and methods of use thereof |
US8623393B2 (en) | 2002-04-29 | 2014-01-07 | Gel-Del Technologies, Inc. | Biomatrix structural containment and fixation systems and methods of use thereof |
US7955288B2 (en) | 2002-12-11 | 2011-06-07 | Ferrosan Medical Devices A/S | Gelatine-based materials as swabs |
US20060115805A1 (en) * | 2002-12-11 | 2006-06-01 | Hansen John E | Gelatine-based materials as swabs |
US20060167540A1 (en) * | 2003-06-17 | 2006-07-27 | Masters David B | Encapsulated or coated stent systems |
US20110118818A1 (en) * | 2003-06-17 | 2011-05-19 | Gel-Del Technologies ,Inc. a corporation | Encapsulated or coated stent systems |
US8465537B2 (en) * | 2003-06-17 | 2013-06-18 | Gel-Del Technologies, Inc. | Encapsulated or coated stent systems |
US9107937B2 (en) | 2003-08-26 | 2015-08-18 | Gel-Del Technologies, Inc. | Wound treatments with crosslinked protein amorphous biomaterials |
US9999705B2 (en) | 2003-08-26 | 2018-06-19 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US8153591B2 (en) | 2003-08-26 | 2012-04-10 | Gel-Del Technologies, Inc. | Protein biomaterials and biocoacervates and methods of making and using thereof |
US8529939B2 (en) | 2003-12-08 | 2013-09-10 | Gel-Del Technologies, Inc. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US20050196440A1 (en) * | 2003-12-08 | 2005-09-08 | Masters David B. | Mucoadhesive drug delivery devices and methods of making and using thereof |
US7923031B2 (en) * | 2004-01-30 | 2011-04-12 | Ferrosan Medical Devices A/S | Haemostatic sprays and compositions |
US20070160543A1 (en) * | 2004-01-30 | 2007-07-12 | Lene Moller | Haemostatic sprays and compositions |
US8021684B2 (en) | 2004-07-09 | 2011-09-20 | Ferrosan Medical Devices A/S | Haemostatic composition comprising hyaluronic acid |
US20070009578A1 (en) * | 2004-07-09 | 2007-01-11 | Lene Moller | Haemostatic composition comprising hyaluronic acid |
US20100143487A1 (en) * | 2007-12-26 | 2010-06-10 | Gel-Del Technologies, Inc. | Biocompatible protein-based particles and methods thereof |
US11890371B2 (en) | 2007-12-26 | 2024-02-06 | Petvivo Holdings, Inc. | Biocompatible protein-based particles and methods thereof |
US20110021964A1 (en) * | 2008-02-29 | 2011-01-27 | Ferrosan Medical Devices A/S | Device for Promotion of Hemostasis and/or Wound Healing |
US8642831B2 (en) | 2008-02-29 | 2014-02-04 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US9533069B2 (en) | 2008-02-29 | 2017-01-03 | Ferrosan Medical Devices A/S | Device for promotion of hemostasis and/or wound healing |
US10016534B2 (en) | 2008-11-17 | 2018-07-10 | Gel-Del Technologies, Inc. | Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof |
US11109849B2 (en) | 2012-03-06 | 2021-09-07 | Ferrosan Medical Devices A/S | Pressurized container containing haemostatic paste |
US9265858B2 (en) | 2012-06-12 | 2016-02-23 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10799611B2 (en) | 2012-06-12 | 2020-10-13 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US9999703B2 (en) | 2012-06-12 | 2018-06-19 | Ferrosan Medical Devices A/S | Dry haemostatic composition |
US10595837B2 (en) | 2013-06-21 | 2020-03-24 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US9724078B2 (en) | 2013-06-21 | 2017-08-08 | Ferrosan Medical Devices A/S | Vacuum expanded dry composition and syringe for retaining same |
US10111980B2 (en) | 2013-12-11 | 2018-10-30 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11103616B2 (en) | 2013-12-11 | 2021-08-31 | Ferrosan Medical Devices A/S | Dry composition comprising an extrusion enhancer |
US11046818B2 (en) | 2014-10-13 | 2021-06-29 | Ferrosan Medical Devices A/S | Dry composition for use in haemostasis and wound healing |
US10653837B2 (en) | 2014-12-24 | 2020-05-19 | Ferrosan Medical Devices A/S | Syringe for retaining and mixing first and second substances |
US10918796B2 (en) | 2015-07-03 | 2021-02-16 | Ferrosan Medical Devices A/S | Syringe for mixing two components and for retaining a vacuum in a storage condition |
CN109561973A (en) * | 2016-08-17 | 2019-04-02 | 联合创新技术有限责任公司 | Fixation device for orthopaedic prosthesis, the annealing device and application method for orthopaedic prosthesis |
US11801324B2 (en) | 2018-05-09 | 2023-10-31 | Ferrosan Medical Devices A/S | Method for preparing a haemostatic composition |
Also Published As
Publication number | Publication date |
---|---|
US5948427A (en) | 1999-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5948427A (en) | Microparticulate surgical adhesive | |
EP1409033B1 (en) | Adhesive including medicament | |
US6162241A (en) | Hemostatic tissue sealants | |
US6066325A (en) | Fragmented polymeric compositions and methods for their use | |
EP1100541B1 (en) | Hydrogel for the therapeutic treatment of aneurysms | |
US8603511B2 (en) | Fragmented polymeric compositions and methods for their use | |
EP0981373B2 (en) | Biofunctional polymers prepared in supercritical fluid | |
CA2201526C (en) | Differentially biodegradable biomedical implants | |
US8303981B2 (en) | Fragmented polymeric compositions and methods for their use | |
US6277394B1 (en) | Collagen-polymer matrices with differential biodegradability | |
CN106983905B (en) | A kind of injectable type self-healing hemostatic material and its preparation method and application | |
WO1999019003A1 (en) | Implantable polymer/ceramic composites | |
WO2008093095A2 (en) | Composition comprising polymer particles | |
JP7021182B2 (en) | Scaffolding materials, methods and uses | |
CN115252875B (en) | Medical tissue adhesive and preparation method thereof | |
CA2339732A1 (en) | Activatable sheet for topical, therapeutic use | |
US9044722B2 (en) | Multi-component, temperature activated, tissue adhesive, sealing, and filling composition | |
WO2015013106A1 (en) | Bone paste compositions and methods of using the same | |
KR20230133361A (en) | Medical tissue adhesive and method for preparing the same | |
Zhai | Alginate microspheres for protein delivery in tissue engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ISCIENCE CORPORATION, CALIFORNIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POINT BIOMEDICAL CORPORATION;REEL/FRAME:011551/0420 Effective date: 20010201 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |